In combination w/ approved chemotherapeutic agents: Management of refractory testicular tumors in patients who received appropriate surgical, chemotherapeutic & radiotherapeutic therapy. 1st line treatment in patients w/ small cell lung cancer.
Administer by slow infusion over a 30-60 min period. Testicular cancer 50-100 mg/m2 daily on days 1 through 5-100 mg/m2 daily on days 1, 3 & 5. Small cell lung cancer 35 mg/m2 daily for 4 days to 50 mg/m2 daily for 5 days. Chemotherapy courses are repeated at 3- to 4-wk intervals after adequate recovery from any toxicity.
Frequently monitor for myelosuppression during & after therapy. Monitor platelet count, Hb & WBC count at the start of therapy & prior to each subsequent cycle. Suspend treatment if platelet count is <50,000 mm3 or ANC is <500 mm3. Severe bone marrow failure not due to malignant disease & severe hepatic dysfunction is contraindicated. Do not administer by rapid IV inj. Risk of toxicity in patients w/ low serum albumin. Women of childbearing potential. Pregnancy & lactation. Childn <2 yr.
Myelosuppression; nausea & vomiting; hypotension; anaphylactic-like reactions (chills, fever, tachycardia, bronchospasm, dyspnea, &/or hypotension); facial/tongue swelling, coughing, diaphoresis, cyanosis, tightness in throat, laryngospasm, back pain &/or loss of consciousness, rash; alopecia.
Drug Interactions
Increased exposure w/ cyclosporine. Additive bone marrow depression may occur w/ bone marrow depressants. Potentiate virus replication, increase side effect &/or decrease Ab response w/ live virus vaccine. Warfarin.
L01CB01 - etoposide ; Belongs to the class of plant alkaloids and other natural products, podophyllotoxin derivatives. Used in the treatment of cancer.
Sign Out
